AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: NCT00494494
Drug: Standard Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical antibiotic for 10 days plus topical corticosteroids for 1 month
Trial: NCT00494494
Drug: nepafenac
RxNorm normalized name: Nepafenac
DrugBank: Nepafenac (DB06802)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: liquid drops, administered three times per day for 1 month in addition to standard care use of topical antibiotic and topical corticosteroid
Trial: NCT05429450
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Three periocular injections of methotrexate at week 0, week 3 and week 6.
Trial: NCT01664143
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of placebo
Trial: NCT01664143
Drug: RO5508887
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple doses of RO5508887
Trial: NCT01790464
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03592121
Drug: AB-101
RxNorm normalized name: Crotalidae immune F(ab')2 Injection [Anavip]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply approximately 1 hour prior to sexual activity
Trial: NCT03592121
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Apply approximately 1 hour prior to sexual activity
Trial: NCT00004412
Drug: Arginine Butyrate
RxNorm normalized name: butyrate
DrugBank: Butyric Acid (DB03568)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: To determine if Arginine Butyrate accelerates healing of refractory leg ulcers over Standard Local Care alone.
Trial: NCT03037788
Drug: WO3979
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT04354428
Drug: Ascorbic Acid
RxNorm normalized name: Ascorbic Acid
DrugBank: Ascorbic acid (DB00126)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants in a household randomized to this study arm will receive ascorbic acid only or ascorbic acid and additional drug therapy
Trial: NCT03037788
Drug: WO3970
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT03037788
Drug: WO3992
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT03037788
Drug: Placebo (WO3988)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Application of cream to each axilla
Trial: NCT00876304
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo capsules every 12 hours for 10 days
Trial: NCT04354428
Drug: Azithromycin
RxNorm normalized name: Azithromycin
DrugBank: Azithromycin (DB00207)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Eligible participants in a household randomized to this study arm will receive hydrochloroquine and azithromycin therapy
Trial: NCT02149342
Drug: Hexylaminolaevulinate cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.2% Hexylaminolaevulinate (Hexvix, Photocure) mixed with Unguentum M (Allmiral) cream (2014)
Trial: NCT02149342
Drug: Methylaminolaevulinate cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: MAL 16% is used as photosensitizer for daylight-PDT
Trial: NCT01462357
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 doses of 0.5 mL supplied as a liquid in individual pre-filled syringes to be administered intramuscularly in the deltoid muscle of the non-dominant arm at Month 2 to maintain blinding.
Trial: NCT01106456
Drug: Pharmacotherapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All participants in the study will be offered pharmacotherapy (e.g. Varenicline, Bupropion, or NRT)
Trial: NCT00113737
Drug: fluoxetine
RxNorm normalized name: Fluoxetine
DrugBank: Fluoxetine (DB00472)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT04354428
Drug: Folic Acid
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Eligible participants in a household will receive folic acid and an additional intervention drug
Trial: NCT04292730
Drug: Standard of Care
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard of Care Treatment for COVID-19 Infection
Trial: NCT02865031
Drug: Decorin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravitreal Injection following ocular trauma to prevent scar tissue formation.
Trial: NCT02582099
Drug: Gentamicin nasal irrigation
RxNorm normalized name: gentamicin Irrigation Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nasal wash with gentamicin solution
Trial: NCT01226719
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 200 mg/m2, 2-hour IV infusion every 2 weeks
Trial: NCT00768729
Drug: MMF or Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 600 mg/m2 MMF taken orally daily or Azathioprine orally daily. Dosage of Azathioprine is dependent on weight. MMF or Azathioprine will be reduced by 25% initially and by 25% every 2 months resulting in complete withdrawal by 6 months.
Trial: NCT01684462
Drug: 0.9 % Normal Saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Infusion of 100 mL of 0.9% Normal Saline ( equivalent volume of Albumin ) over 4\~8h, commencing within 12 hours of stroke onset
Trial: NCT02028494
Drug: Capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Two dosages comparison
Trial: NCT01574703
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: All dosing to have taken place per study A3051123
Trial: NCT01639027
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Women who will receive 2ml of normal physiological saline (0.9% sodium chloride) I.V at the start of the active phase of labor.
Trial: NCT00157833
Drug: Artekin / Coartemther
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT01831232
Drug: pravastatin sodium
RxNorm normalized name: Pravastatin Sodium
DrugBank: Pravastatin (DB00175)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Given PO
Trial: NCT01607983
Drug: inhaled nitric oxide
RxNorm normalized name: nitric oxide Inhalant Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20 parts per million (ppm) of inhaled nitric oxide
Trial: NCT03765294
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Film-coated tablet for oral use
Trial: NCT01563068
Drug: Calcipotriene 0.005% Foam
RxNorm normalized name: CALCIPOTRIENE 0.005% FOAM,TOP
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical application applied twice a day for 15 days
Trial: NCT01880307
Drug: Azathioprine
RxNorm normalized name: Azathioprine
DrugBank: Azathioprine (DB00993)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00360074
Drug: Thyroxin, Triiodothyronine
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT00308711
Drug: Dinoprostone vaginal insert (Cervidil)
RxNorm normalized name: dinoprostone Vaginal Insert
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrogel polymer intravaginal insert with retrieval system. One insert is to remain in the posterior fornix of the vagina until removed for one of the following conditions: onset of active labor; maternal/fetal complication, e.g. non-reassuring fetal heart rate. Record if the insert falls out prior to meeting one of the first two criteria. In no case is the insert to remain in place longer than 24h.
Trial: NCT02167256
Drug: AZD0530 125mg daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients with plasma drug level \<100ng/ml after 2 weeks of 100mg AZD0530 daily will receive 125mg daily of AZD0530.
Trial: NCT02167256
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50% of patients will receive placebo treatment for the duration of the study.
Trial: NCT01880307
Drug: Prednisolon
RxNorm normalized name: Prednisolone
DrugBank: Prednisolone acetate (DB15566)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT03470337
Drug: Phlogenzym
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bromelain / Trypsin / Rutoside
Trial: NCT01666223
Drug: Chenodeoxycholic Acid
RxNorm normalized name: Chenodeoxycholic acid
DrugBank: Chenodeoxycholic acid (DB06777)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.250 mg dissolved in 100 ml saline, administered in a feeding tube at time = 0.
Trial: NCT01666223
Drug: Colesevelam 3750 mg + chenodeoxycholic acid 1250 mg
RxNorm normalized name: colesevelam hydrochloride 3750 MG
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam and chenodeoxycholic acid dissolved in 100 ml saline, administered in a duodenal tube at time = 0.
Trial: NCT03467425
Drug: FF/UMEC/VI
FDA approved: no
EMA approved: no
PMDA approved: no
Description: FF is a dry white powder containing 100 mcg GW685698 blended with lactose in one blister in the first strip of the DPI. UMEC/VI is a dry white powder containing 62.5 mcg of UMEC and 25 mcg of VI per blister, both blended together with lactose and magnesium stearate in the second strip of the DPI.
Trial: NCT03467425
Drug: Inhaled Corticosteroid
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled Corticosteroid (ICS) as prescribed by the physician.
Trial: NCT03467425
Drug: COPD rescue medications
RxNorm normalized name: ALLERGENIC EXTRACT, MEADOW FESCUE POLLEN
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rescue medications for COPD will be prescribed and obtained according to usual practice.
Trial: NCT04044417
Drug: curcumin simvastatin paste
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Curcumin is the primary active constituent of turmeric. Simvastatin is chemical modification of lovastatin.
Trial: NCT04044417
Drug: EDTA root conditioning
FDA approved: no
EMA approved: no
PMDA approved: no
Description: EDTA is an aminopolycarboxylic acid and a colourless, water-soluble solid
Trial: NCT01313429
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 50 mg PO BID for 7 days prior to the first dose of vaccine and then on days 8 through 14, and 22 through 28 of each treatment cycle.
Trial: NCT01313429
Drug: Celecoxib
RxNorm normalized name: Celecoxib
DrugBank: Celecoxib (DB00482)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 400 mg PO BID for 7 days prior to the first dose of vaccine and then on days 1 through 28 of each vaccine cycle.
Trial: NCT00712296
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo 6 capsules twice a day
Trial: NCT01176552
Drug: GM-CSF, IFN alpha and IL-2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment during 6 months: GM-CSF, 1 mcg/kg, 3 times per week, subcutaneously, first week of each month; IFN, 10 MIU, 3 times per week, subcutaneously, second week, and IL-2, 1 MIU, 3 tiw, intravenously, third week. Fourth week of each month was free from treatment.
Trial: NCT04150224
Drug: PBTZ169 640 mg OD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two administrations once a day with a wash-out period: food effect
Trial: NCT04150224
Drug: PBTZ169 640 mg BiD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Twice a day fasted; 1 day of administration
Trial: NCT04150224
Drug: PBTZ169 1280 mg MD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once a day after meal, 14 doses
Trial: NCT00569686
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo
Trial: NCT03788733
Drug: Melatonin 3 mg
RxNorm normalized name: melatonin 3 MG
DrugBank: Melatonin (DB01065)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 time a day for 8 weeks
Trial: NCT03788733
Drug: Placebo Oral
RxNorm normalized name: placebo ORAL TABLET
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 time a day for 8 weeks
Trial: NCT00352612
Drug: clindamycin
RxNorm normalized name: Clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: clindamycin suspension or tablets, 20mg/kg/day, given by mouth, divided TID, for 7 days
Trial: NCT01321801
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preoperative administration of a matching placebo
Trial: NCT03597516
Drug: Placebos
FDA approved: no
EMA approved: no
PMDA approved: no
Description: powder for reconstitution for oral administration
Trial: NCT01330758
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg AZD8931 wet granulation tablet formulation
Trial: NCT01330758
Drug: AZD8931
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg AZD8931 roller compacted tablet formulation
Trial: NCT01356433
Drug: oral vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: cross-over study,2 arms Arm 1(50cases): is given oral vitamin C 200mg per day in the first 3 months, then stop oral VitC for the next 3 months.~Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Trial: NCT01356433
Drug: oral vitamin C
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Arm 2(50cases): is not given vitamin C in the first 3 months, then switch to receive oral VitC 200mg per day in the next 3 months.
Trial: NCT00701129
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Administered subcutaneously.
Trial: NCT02412631
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo for lorcaserin
Trial: NCT02932891
Drug: DSXS topical
FDA approved: no
EMA approved: no
PMDA approved: no
Description: topical treatment
Trial: NCT04181346
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo
Trial: NCT02177266
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The placebo will match the study drug.
Trial: NCT03304899
Drug: RiaSTAP Injectable Product
RxNorm normalized name: RiaSTAP Injectable Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: RiaSTAP, Fibrinogen Concentrate (Human) is a human blood coagulation factor indicated for the treatment of acute bleeding episodes.~Dose (mg/kg body weight) =~(\[Target level (mg/dL) - measured level (mg/dL)\])/(1.7 (mg/dL per mg/kg body weight))
Trial: NCT01367808
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: The subjects will be given placebo twice a day for 5 days prior to the study
Trial: NCT03364049
Drug: MK-7162
RxNorm normalized name: vitamin MK 7
FDA approved: no
EMA approved: no
PMDA approved: no
Description: oral tablets
Trial: NCT04038489
Drug: Doxorubicin
RxNorm normalized name: Doxorubicin
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Doxorubicin (60 mg/m2) Given by IV with cyclophosphamide
Trial: NCT04038489
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Cyclophosphamide (600 mg/m2) Given by IV with doxorubicin
Trial: NCT00546715
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Solution, Oral, Single Dose
Trial: NCT00755079
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: An ambiguous sheathing capsule will be placed over a lactose placebo pill. The placebo will have no effect on pulmonary function.
Trial: NCT01369875
Drug: Cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 60 mg/kg/day X 2 days intravenous (IV) over 1 hour on days -7 and -6
Trial: NCT00630045
Drug: neoadjuvant chemotherapy with oxaliplatin and capecitabine
RxNorm normalized name: Capecitabine
DrugBank: Capecitabine (DB01101)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: oxaliplatin: 130mg/m2, d1(Q3w) capecitabine:1000mg/m2 bid, d1-14(Q3w)
Trial: NCT01993108
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: One dose of placebo one hour before fMRI scanning.
Trial: NCT04341480
Drug: Chemotherapy
RxNorm normalized name: Chemotherapy Glove SML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Routine chemotherapy for individual tumor type.
Trial: NCT00577122
Drug: Medroxyprogesterone with Cyclophosphamide + Methotrexate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medroxyprogesterone Acetate Dose 1000 mg po daily Cyclophosphamide Dose 50 mg po daily Methotrexate Dose 2.5 mg po daily Days 1 and 2 of each week
Trial: NCT01340976
Drug: LY2787106
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Administered IV.
Trial: NCT02953821
Drug: Placebo Gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mL (0 Units) given by a shot under the skin (via subcutaneous injection)
Trial: NCT00782210
Drug: placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olodaterol (BI1744) placebo inhaled orally once daily from the Respimat inhaler
Trial: NCT04447092
Drug: Leucovorin
RxNorm normalized name: Leucovorin
DrugBank: Leucovorin (DB00650)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Leucovorin 400 mg/m2 iv D1 (every 2 weeks)
Trial: NCT04447092
Drug: 5FU
RxNorm normalized name: Fluorouracil
DrugBank: Fluorouracil (DB00544)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 5-FU 2400 mg/m2 iv over 46 hours D1 (every 2 weeks)
Trial: NCT00654381
Drug: BI 1356 placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: once daily
Trial: NCT03641573
Drug: [14C] ASN002
FDA approved: no
EMA approved: no
PMDA approved: no
Description: \[14C\] ASN002
Trial: NCT00628550
Drug: Epinephrine
RxNorm normalized name: Epinephrine
DrugBank: Epinephrine (DB00668)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: One standard dose epinephrine (0.01 mg/kg) intravenously rescue as the second vasopressor medication.
Trial: NCT00774098
Drug: dextrose 10% (D10W ®) infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Started at 8pm the day before surgery until the procedure begins
Trial: NCT03050905
Drug: VEKIRAX
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Patients will be treated according to label recommendation as for GT1b (with and without cirrhosis) for 12 weeks. All subjects will receive Ombitasvir+Paritaprevir+Ritonavir (Viekirax).~Study Regimen: ombitasvir+paritaprevir+ritonavir (25+150+100mg once daily)
Trial: NCT00251394
Drug: 1018 ISS
RxNorm normalized name: 1018 ISS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Given as an injection under the skin after the 2nd, 3rd and 4th rituxan infusion. One week after the last rituxan infusion is given, a fourth and final 1018ISS injection will be given.
Trial: NCT01834404
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo pills matched the study drug in appearance for the 2 dose levels.
Trial: NCT00754247
Drug: Cetearyl alcohol lotion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo is cetearyl alcohol lotion with no steroids, silicone, vitamin E, or onion extract and will be applied 2 times a day to the lesion.
Trial: NCT03018353
Drug: Patients receiving Sof/Vel (Epclusa) and Navigation services
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Implementing HCV treatment in the jails using FDA-approved medications and continuing there treatment in the community if they are released during their treatment regimen.
Trial: NCT01470469
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily oral dosing in the evening for 12 weeks.
Trial: NCT03242499
Drug: Lovastatin
RxNorm normalized name: Lovastatin
DrugBank: Lovastatin (DB00227)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Lovastatin 80mg or placebo use for 48 weeks.
Trial: NCT03242499
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: placebo for 48 weeks
Trial: NCT00482391
Drug: cyclophosphamide
RxNorm normalized name: Cyclophosphamide
DrugBank: Cyclophosphamide (DB00531)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Trial: NCT00482391
Drug: doxorubicin hydrochloride
RxNorm normalized name: Doxorubicin Hydrochloride
DrugBank: Doxorubicin (DB00997)
FDA approved: yes
EMA approved: no
PMDA approved: no
Trial: NCT02611492
Drug: Methotrexate
RxNorm normalized name: Methotrexate
DrugBank: Methotrexate (DB00563)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: 1 g/m2 continuous Intravenous Infusion (CIV) D1 cycles 2 and 4 25 mg/m2 per os D1, D8 interphase
Trial: NCT02611492
Drug: 6 Mercaptopurine (6MP)
RxNorm normalized name: 6-Mercaptopurine
DrugBank: Mercaptopurine (DB01033)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: 60 mg/m2 per os, D1 to D14, interphase
Trial: NCT04498962
Drug: Danzhu Fuyuan Granule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Danzhu Fuyuan Granules，2 times / day, 1 bag / time, one time in the morning and one time in the evening. It is recommended to add the same amount of boiling water as the particles to soak for 30 seconds, and then add 5 times boiling water to dissolve until completely dissolved.The treatment cycle of each arm: 8 weeks for Chronic Stable Angina, 6 months for Vascular Dementia and 6 months for Idiopathic Membranous Nephropathy.
Trial: NCT01110629
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: daily dose: 3 tablets TID for 8 weeks.
Trial: NCT00197379
Drug: roxithromycin
RxNorm normalized name: roxithromycin
DrugBank: Roxithromycin (DB00778)
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03081416
Drug: Normal saline
RxNorm normalized name: Normal Saline Flush
FDA approved: no
EMA approved: no
PMDA approved: no
Trial: NCT03081416
Drug: Ketorolac
RxNorm normalized name: Ketorolac
DrugBank: Ketorolac (DB00465)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: standard therapy
Trial: NCT01416883
Drug: ICI176,334-1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subject will receive single dose of ICI176,334-1
Trial: NCT02151708
Drug: Placebo
RxNorm normalized name: placebo
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Eligible subjects were randomly allocated in a 1:1:1 ratio to receive either 90mg motilitone or 180mg motilitone or placebo motilitone three times daily for 2weeks.